Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

Trial Identifier: D9106C00002
Sponsor: AstraZeneca
Start Date: February 2024
Primary Completion Date: January 2026
Study Completion Date: August 2027
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Wien, AT, 1140
AT Wien, AT, 1130
CA, ON Kingston, ON, CA, K7L 2V7
CA, QC Chicoutimi, QC, CA, G7H 5H6
CA, QC Montréal, QC, CA, H4A 3J1
CZ Brno, CZ, 625 00
CZ Olomouc, CZ, 77900
CZ Prague, CZ, 12808
CZ Praha 5, CZ, 150 06
DE Berlin, DE, 13125
DE Grosshansdorf, DE, 22927
DE Köln, DE, 51109
DE Moers, DE, 47441
DE Würzburg, DE, 97074
ES Barakaldo, ES, 48903
ES Barcelona, ES, 08025
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28046
ES Madrid, ES, 28007
ES Madrid, ES, 28027
ES Pamplona, ES, 31008
ES Valencia, ES, 46009
ES Zaragoza, ES, 50009
FR La Tronche, FR, 38700
FR MARSEILLE, FR, 13008
FR Montpellier, FR, 34295
FR Mulhouse, FR, 68070
FR PARIS CEDEX 5, FR, 75005
FR Pessac, FR, 33604
FR POITIERS, FR, 86000
FR Toulouse, FR, 31059
HU Budapest, HU, 1122
HU Törökbálint, HU, 2045
IT Bari, IT, 70124
IT Bologna, IT, 40138
IT Milan, IT, 20141
IT Milano, IT, 20132
IT Milano, IT, 20133
IT NAPOLI, IT, 80131
IT Palermo, IT, 90127
IT Pavia, IT, 27100
IT PESCHIERA DEL GARDA, IT, 37019
PT Lisboa, PT, 1500-650
PT Lisboa, PT, 1350-352
SE Solna, SE, 171 64
SE Uppsala, SE, SE-751 85
US, NY Bronx, NY, US, 10467
US, TX Houston, TX, US, 77030
US, VA Charlottesville, VA, US, 22908